Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Cramer Loves These Dividend Stocks
09:31am, Monday, 01'st Sep 2025
Key Points Jim Cramer's Mad Money offers insights valuable to income investors, despite his broader focus on growth.
Novo's Wegovy Beats Lilly's Zepbound for Heart Health, Study Finds. What It Means for Stocks.
06:39am, Monday, 01'st Sep 2025
The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.
Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly's Obesity Drug
03:30am, Monday, 01'st Sep 2025
The study used evidence gathered from patient experiences rather than a controlled trial, Novo said.
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
12:30pm, Sunday, 31'st Aug 2025
Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world compar
Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans
01:44pm, Friday, 29'th Aug 2025
Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI
Eli Lilly joins forces with China tech giant to expand obesity drug market
06:04am, Friday, 29'th Aug 2025
Eli Lilly has partnered with a leading Chinese tech company, JD Health to fast-track its presence in China's rapidly expanding obesity drug market, boosting the company's global growth in the weight-l
Stock Of The Day: Another Breakout For Eli Lilly?
01:49pm, Thursday, 28'th Aug 2025
Trading is quiet in Eli Lilly and Co LLY on Thursday. The stock has stalled out at a resistance level.
Eli Lilly: Orals Unlock The Next Wave Of Obesity Drug Adoption
11:07am, Thursday, 28'th Aug 2025
Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron'
2 Growth Stocks That Could Be Worth $1 Trillion in 5 Years
09:45am, Thursday, 28'th Aug 2025
In 2018, Apple became the first publicly traded company to reach a $1 trillion market capitalization. Several more have joined that club since, but it remains highly exclusive, with fewer than 10 memb
Stevens Capital Closes Out Position in Eli Lilly
05:39am, Thursday, 28'th Aug 2025
According to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling al
Eli Lilly halts UK shipments of Mounjaro diabetes and weight-loss drug
04:14am, Thursday, 28'th Aug 2025
Eli Lilly and Co (NYSE:LLY) has halted shipments of its Mounjaro diabetes and weight-loss drug to the UK ahead of a planned price hike next month. Earlier this week the US drug giant warned against "
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro
06:38pm, Wednesday, 27'th Aug 2025
Eli Lilly has temporarily paused shipments of its weight-loss drug Mounjaro in the UK, ahead of a new price hike for the treatment set to come into effect starting next month.
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
09:15am, Wednesday, 27'th Aug 2025
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
Eli Lilly's Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race
08:23am, Wednesday, 27'th Aug 2025
Key Points in This Article: Eli Lilly's (LLY) Zepbound has outshone Novo Nordisk's Wegovy, achieving superior weight-loss results in clinical trials.
The bear case on Eli Lilly has played out, says only firm to have called it a sell
07:25am, Wednesday, 27'th Aug 2025
The bear case for Eli Lilly has now played out following the reaction to the drugmaker's oral obesity drug trial, an analyst said Wednesday in upgrading the stock.
